Following ASCO 2024, Mark A. Lewis, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to provide comprehensive insights on recent updates from the ESOPEC trial in esophageal adenocarcinoma.
Zolbetuximab Scores FDA Approval in CLDN 18.2+ Gastric/GEJ Cancer
This approval marks the first CLDN 18.2-targeted therapy in this patient population.
Read More
LaPelusa’s Journey in the Dynamic Field of GI Oncology
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
Listen
Trial of PT886 and Pembrolizumab Doses First Patient With Gastric/GEJ Cancer
The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with pembrolizumab.
Unpacking the Latest Research in Gastrointestinal Cancers
In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.
FDA Approves Cologuard Plus Stool DNA Test for Colorectal Cancer Screening
The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.
Assessing Targeted PET Imaging for Advanced Rectal Cancer
In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer.